Pro-Dex(US:PDEX)2025-05-01 20:03Financial Performance - Net sales for Q3 2025 increased by $3.1 million, or 22%, to $17.4 million compared to $14.3 million in Q3 2024, driven by $6.2 million shipments of the next generation orthopedic handpiece [3] - Gross profit for Q3 2025 rose by $1.8 million, or 45%, to $5.8 million from $4.0 million in Q3 2024, reflecting a favorable product mix [4] - Operating income for Q3 2025 increased by $1.4 million, or 65%, to $3.6 million compared to $2.2 million in Q3 2024 [6] - Net income for Q3 2025 was $3.3 million, or $0.98 per diluted share, compared to $655,000, or $0.19 per diluted share, in Q3 2024 [7] - For the nine months ended March 31, 2025, net sales increased by $10.3 million, or 27%, to $49.1 million from $38.8 million in the same period of 2024 [8] - Gross profit for the nine months ended March 31, 2025, increased by $5.6 million, or 53%, compared to the same period in fiscal 2024 [9] - Operating income for the nine months ended March 31, 2025, rose by $4.5 million, or 94%, to $9.3 million compared to $4.8 million in the prior year [11] - Net income for the nine months ended March 31, 2025, was $7.8 million, or $2.31 per diluted share, compared to $540,000, or $0.15 per diluted share, for the same period in fiscal 2024 [12] Assets and Liabilities - Total current assets as of March 31, 2025, were $49.9 million, up from $36.6 million as of June 30, 2024 [17] - Total liabilities as of March 31, 2025, were $29.0 million, compared to $21.6 million as of June 30, 2024 [17]